based on 33 analysts
46.88%
Buy
31.25%
Hold
21.88%
Sell
Based on 33 analysts offering long term price targets for Zydus Lifesciences Ltd. An average target of ₹1083.36
Source: S&P Global Market Intelligence
Zydus Lifesciences Ltd price forecast by 33 analysts
Upside of10.72%
High
₹1380
Target
₹1083.36
Low
₹794
Zydus Lifesciences Ltd target price ₹1083.36, a slight upside of 10.72% compared to current price of ₹978.5. According to 33 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Zydus Lifesciences Ltd revenue growth forecast
Expected growth rate Q1, FY2026:24.31%
Forecast
Actual
Including amortisation and stock based compensations
Zydus Lifesciences Ltd EPS growth forecast
EPS estimate Q1, FY2026:20.13%
Forecast
Actual
Source: S&P Global Market Intelligence
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | + 2.2 % |
3 Month Return | -12.31 % |
1 Year Return | + 51.99 % |
Market Stats | |
Previous Close | ₹976.50 |
Open | ₹981.00 |
Volume | 6.51L |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹98,258.75Cr |
P/E Ratio | 22.94 |
PEG Ratio | 1.54 |
Market Cap | ₹98,258.75 Cr |
P/B Ratio | 6.43 |
EPS | 38.31 |
Dividend Yield | 0.3 |
Sector | Pharmaceuticals |
ROE | 23.45 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
HOLD | ₹98,258.75 Cr | 54.87% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
BUY | ₹14,194.43 Cr | -2.04% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
BUY | ₹71,168.10 Cr | 33.12% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
BUY | ₹61,090.14 Cr | 23.08% | 0.53 | NA | NA | |
BUY | ₹39,032.84 Cr | 7.26% | 0.56 | ₹589 Cr | ₹3,453 Cr |
Organisation | Zydus Lifesciences Ltd |
Headquarters | Ahmedabad |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Zydus Lifesciences Ltd
Zydus Group's IMKELDI Receives USFDA Approval - 27 Nov, 2024
Zydus Lifesciences Receives Buy Rating with Target Price - 19 Nov, 2024
Zydus Lifesciences Faces Legal Setback Over Sigrima - 18 Nov, 2024
Zydus Lifesciences Target Price Adjusted Amid Challenges - 14 Nov, 2024
Zydus Lifesciences Reports Strong Q2 Performance - 13 Nov, 2024
Zydus Lifesciences Acquires Stake in Mylab - 12 Nov, 2024
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Retail Holding Up
Retail Investor have increased holdings from 6.80% to 6.85% in Sep 2024 quarter
FII Holding Up
Foreign Institutions have increased holdings from 5.59% to 7.52% in Sep 2024 quarter
Promoter Holding Unchanged
Promoters holdings remained unchanged at 74.98% of holdings in Sep 2024 quarter
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 136.8% return, outperforming this stock by 26.6%
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 62.8% return, outperforming this stock by 10.8%
Profit Down
Netprofit is down for the last 2 quarters, 1.41K Cr → 911.2 Cr (in ₹), with an average decrease of 35.8% per quarter
Price Dip
In the last 3 months, ZYDUSLIFE stock has moved down by -12.7%
Revenue Fall
Revenue is down for the last 2 quarters, 6.27K Cr → 5.30K Cr (in ₹), with an average decrease of 15.4% per quarter
MF Holding Down
Mutual Funds have decreased holdings from 7.24% to 6.57% in Sep 2024 quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 74.98% | 0.00 | |
Foreign Institutions | 7.52% | 34.61 | |
Mutual Funds | 6.57% | ||
Retail Investors | 6.85% | 0.71 | |
Others | 4.08% |
Zydus Lifesciences Ltd in the last 5 years
Lowest (7.34x)
March 7, 2022
Today (22.94x)
December 13, 2024
Industry (56.50x)
December 13, 2024
Highest (34.62x)
March 26, 2024
Zydus Lifesciences Ltd’s net profit jumped 13.8% since last year same period to ₹911.20Cr in the Q2 2024-2025. On a quarterly growth basis, Zydus Lifesciences Ltd has generated -35.83% fall in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending March 2024, Zydus Lifesciences Ltd has declared dividend of ₹3 - translating a dividend yield of 0.92%.
Read More about DividendsBearish
Neutral
Bullish
Zydus Lifesciences Ltd is currently in a Bearish trading position according to technical analysis indicators.
Zydus Lifesciences Ltd (ZYDUSLIFE) share price today is ₹978.5
Zydus Lifesciences Ltd is listed on NSE
Zydus Lifesciences Ltd is listed on BSE
PE Ratio of Zydus Lifesciences Ltd is 22.94
PE ratio = Zydus Lifesciences Ltd Market price per share / Zydus Lifesciences Ltd Earnings per share
Today’s traded volume of Zydus Lifesciences Ltd(ZYDUSLIFE) is 6.51L.
Today’s market capitalisation of Zydus Lifesciences Ltd(ZYDUSLIFE) is ₹98258.75Cr.
Zydus Lifesciences Ltd(ZYDUSLIFE | Price |
---|---|
52 Week High | ₹1324.3 |
52 Week Low | ₹633.3 |
Zydus Lifesciences Ltd(ZYDUSLIFE) share price is ₹978.5. It is down -26.11% from its 52 Week High price of ₹1324.3
Zydus Lifesciences Ltd(ZYDUSLIFE) share price is ₹978.5. It is up 54.51% from its 52 Week Low price of ₹633.3
Zydus Lifesciences Ltd(ZYDUSLIFE | Returns |
---|---|
1 Day Returns | 2% |
1 Month Returns | 2.2% |
3 Month Returns | -12.31% |
1 Year Returns | 51.99% |